ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Zurich-based KOVE Medical closed €1.7 million (CHF 1.6 million) to develop an implantable device reducing preterm birth risk after foetal surgery. The angel-backed round funds progress toward First-in-Human studies. CEO and co-founder Yannick Devaud acknowledged the team and investors.
Tap to vote and see what everyone thinks.
Summary by ByteBrief